Scientists say that melatonin inhibits the development of anemia with round-the-clock coverage – Science – TASS
Now experts are developing a drug based on it.
NOVOSIBIRSK, December 24. / Tass /. Scientists of the Institute of Cytology and Genetics (ICIG) of the Siberian Branch (SB) of the RAS found that melatonin (a circadian rhythm regulator) prevents the development of anemia in mice living around the clock, reported in the official publication of the Siberian Branch of the RAS in Science in Siberia.
“The introduction of melatonin, which helps to adapt to violations of the light regime, prevents the development of anemia in mice kept under constant light. Compared with the group that received a placebo, by the end of the experiment, the animals receiving melatonin significantly increased hemoglobin content”, – quotes Press Service of the Chief Researcher of the Institute of Clinical and Experimental Lymphology (a branch of the ICIG SB RAS) Svetlana Michurina.
According to Tass Michurin, the findings also apply to people, which can be useful, in particular, for those living in the Arctic zone. “People who live in circumpolar zones, where the lighting rhythms are broken, or who work in shifts, melatonin is destroyed, which leads to a violation of biorhythm. The results — an obstacle to anemia with melatonin — can be transferred to people,” she noted.
The experiment was carried out on two groups of mice: one were kept in the permanently on light, the control group – in the standard mode with 14 hours of light and 10 hours of darkness. In mice constantly living in the light, we found signs characteristic of anemia – a decrease in the volume of red blood cells, a decrease in the content of red blood cells and hemoglobin.
Michurina added that now the institute is developing a drug based on melatonin. “We created a composition where a melatonin molecule is implanted on a silicon matrix. This new drug provides a metered release of melatonin, which corresponds to the natural rhythm of its secretion,” she said. The drug is under development and has not yet passed clinical trials.